Brought to you by

Amgen, Molecular Partners team up in immuno-oncology deal
20 Dec 2018
Executive Summary
Molecular Partners AG licensed Amgen Inc. exclusive worldwide rights to develop and commercialize its cancer candidate MP0310.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com